A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

A Phase 1, Single-Center, Open-Label Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

Ascending dose, 7-day, open label safety trial of SPX-101 Inhalation Solution in adult subjects with cystic fibrosis.

Inclusion Criteria:

• Confirmed diagnosis of CF
• FEV1 ≥ 40% predicted normal
• Stable CF lung disease
• Non-pregnant, non-lactating females

Exclusion Criteria:

• Significant unstable co-morbidities within 28 days of screening as judged by the Investigator.
• Has received an investigational drug within the past 30 days